To explore whether PPARγ activation mediates the therapeutic effect of Alp on cancer cachexia, we used the PPARγ inhibitor GW9662 (10 μM, the dose selection was based on the tumor cell model (Seargent et al., 2004)) and assessed its impact on myotube atrophy in vitro. Here, PPARG is linked to cancer.